IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-05-07 (newstrail.com)
Digital Health Revolution Fuels Growth in Patient Engagement Solution Market -
Patient Engagement Solutions Market Overview
Read more
2025-05-06 (cmoney.tw)
IQVIA Q1 2025 Revenue exceeds expectations! AI deployment and TAS growth help future prospects
IQVIA's revenue performance in Q1 2025 was outstanding. CEO Ari Bousbib announced that it would raise its revenue guidance for 2025, mainly benefiting from TAS growth and AI technology expansion kit.
Read more
2025-04-29 (pharmexec.com)
Asembia 2025: A General Landscape of the Pharmaceutical Industry
IQVIA's Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.
Read more
2025-04-23 (businesswire.com)
IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global i...
Read more
2025-03-27 (plos.org)
Assessing concentration in the monoclonal antibody innovation market: A patent-based study | One
BACKGROUND Monoclonal antibodies (mAbs) are revolutionizing healthcare treatments due to their high efficacy and relative safety, despite their cost. Since they first appeared in the late 1980s, a rapidly growing market has developed. OBJECTIVE This study aims to analyze concentration levels in the market for mAb innovations through a quantitative patent analysis. Data were analyzed using traditional concentration indicators such as the Herfindahl-Hirschman Index and Concentration Ratio, as well as linear regression and kernel density graphs to evaluate innovation and global technology dissemination strategies. The starting point was patents associated with mAbs registered by the FDA and identified in the IQVIA database up until 2019, and supplemented by data from The Antibody Society, Purple Book, Orange Book, and FDA. RESULTS Our findings indicate that the market for mAb innovations is moderately concentrated for general patents and unconcentrated for priority patents. However, it is significantly more
Read more
2025-03-25 (nutraingredients-asia.com)
IQVIA and NUS join forces to boost healthspan, innovate personalised health solutions
Data science company IQVIA and the National University of Singapore (NUS) are set to embark on several joint efforts to advance longevity medicine and personalised health innovations.
Read more
2025-03-21 (zorginnovatie.nl)
National AI in Surge Congress |
On May 20, 2025, the very first National AI in Healthcare Congress takes place in the Muziekgebouw aan 't IJ in Amsterdam. This congress is organized by the NL AIC Working Group Health and Care and IQVIA. This event brings healthcare professionals together to learn about the possibilities of AI in the healthcare sector. The congress has no profit motive. This is important to the NL AIC, so that participation among care providers becomes as high as possible. During this congress you will discover how AI can contribute to more efficient care processes, reduce administrative burdens and address ethical and legal issues surrounding AI. The carefully composed program, developed by a scientific steering group, offers practical examples of successful AI projects and valuable insights that are directly applicable to your work. Register the program 09: 00-10: 00 Reception and coffee 10: 00-10:30 AM History, Impact and Future | Diederik Gommers, Intensivist & department head Intensive Care, Erasmus MC 10: 30 - 11:00
Read more
2025-03-10 (stocktitan.net)
IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services | IQV Stock News
IQVIA (NYSE:IQV) has been recognized as a leader in the IDC MarketScape's 2024 assessment for decentralized clinical trial (DCT) technologies and consulting services. The company's leadership position is attributed to its extensive network of over 200 DCT consultants, comprehensive DCT-enabling technologies, and expertise in regulatory strategy implementation.IDC's first assessment of DCT technology solutions highlights IQVIA's strengths in:Deep clinical and DCT implementation strategy expertise across therapeutic areasHealthcare-grade AI implementation across the value chainNovel GenAI tools for enhanced patient experienceCountry-wise regulatory strategy expertiseDecentralized clinical trials, which gained momentum during COVID-19, utilize telemedicine and mobile technologies to conduct trial activities remotely. This approach enables patient monitoring through wearable devices and digital tools, reducing the need for in-person site visits.
Read more
2024-12-23 (businesswire.com)
Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute
Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in sco...
Read more
2024-10-23 (lifescienceleader.com)
AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development
Part two of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the...
Read more